peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GHRP / ghrelin mimetic

Ipamorelin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

This statement only establishes that ipamorelin was within the review’s scope; it does not provide peptide-specific efficacy or safety findings. The reviewers searched PubMed for ipamorelin along with musculoskeletal tissue terms using PRISMA guidelines. Emax expressed as percent of a reference agonist (GHRP-6) indicates maximal efficacy relative to that comparator; here it was 85.0%.

Sources for this introduction: [1] [2] [3]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

This statement only establishes that ipamorelin was within the review’s scope; it does not provide peptide-specific efficacy or safety findings.

Sources[2]pubmedPeptide Supplements and Their Therapeutic Applications in Sports Medicine.To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models.”

    Peptide Supplements and Their Therapeutic Applications in Sports Medicine. · PURPOSE

    pubmed:42578445:9b8b12ec3690:9b8b12ec3690

How does it work?

Target, response, and disposition.

Mechanism

The reviewers searched PubMed for ipamorelin along with musculoskeletal tissue terms using PRISMA guidelines.

Sources[2]pubmedPeptide Supplements and Their Therapeutic Applications in Sports Medicine.Three independent reviewers searched the PubMed database using permutations of peptide search terms (BPC-157, TB-500, CJC-1295, MK-677 [ibutamoren], ipamorelin, and GHK-Cu) combined with musculoskeletal tissue search terms (bone, fracture, muscle, tendon, ligament, meniscus, and cartilage) following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Three independent reviewers searched the PubMed database using permutations of peptide search terms (BPC-157, TB-500, CJC-1295, MK-677 [ibutamoren], ipamorelin, and GHK-Cu) combined with musculoskeletal tissue search terms (bone, fracture, muscle, tendon, ligament, meniscus, and cartilage) following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.”

    Peptide Supplements and Their Therapeutic Applications in Sports Medicine. · METHODS

    pubmed:42578445:9b8b12ec3690:9b8b12ec3690

What has been studied?

What the evidence says.

Comparative evidence

Emax expressed as percent of a reference agonist (GHRP-6) indicates maximal efficacy relative to that comparator; here it was 85.0%.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL58547Assay: Efficacy was determined as percent of GHRP-6 in rat pituitary cell assay tested in vitro Assay format: organism-based format Standard result: Emax = 85.0 %
Reported result
Emax = 85.0 %
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Assay: Efficacy was determined as percent of GHRP-6 in rat pituitary cell assay tested in vitro Assay format: organism-based format Standard result: Emax = 85.0 %”

    ChEMBL activities for CHEMBL58547 · Activity 235793

    chembl-activities:chembl58547:be3496bede2f:be3496bede2f

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, regulatory, safety
  • 35 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (25), assurance_score_below_0.72 (9), current_regulatory_source_required (3), extraction_ambiguity (39), high_risk_requires_regulatory_or_two_independent_sources (9), no_direct_support (33)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. ChEMBL activities for CHEMBL58547 ↗

    chembl-activities · published 2026-08-27 · retrieved 2026-08-27T19:16:08Z

  2. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. ↗

    pubmed · published 2026-08-11 · retrieved 2026-08-25T22:58:23Z

Publication history and provenance

Version 8 · Automated assessment · 2026-08-27T19:16:08Z

af1f7839ba0a543ba5443af8ac6ea8c64847cbe692c8a921abe12b1f467e6eed